Rock Springs Capital
Baltimore, Maryland, United StatesFounded 2013
Rock Springs Capital is a hedge fund primarily focused on investing in the healthcare and life sciences sectors. The firm employs a fundamental, research-driven, long/short equity strategy, specializing in growth equity and late-stage venture capital investments in companies with promising growth prospects and strong management teams.
Portfolio
10
Fund Size
$5.8B
Top Stage
Series B
Last 12 Mo
0
Stage Distribution
Portfolio
10 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Leap Therapeutics | Series B | $40M | Apr 2024 |
| Hemab Therapeutics | Series B | $135M | Feb 2023 |
| Mineralys Therapeutics, Inc. | Series B | $118M | Jun 2022 |
| Disc Medicine | Series B | $90M | Sep 2021 |
| MiRXES Pte | Series C | $77M | Jul 2021 |
| DELFI Diagnostics, Inc. | Series A | $100M | Jan 2021 |
| Athira Pharma, Inc. | Series B | $85M | Jun 2020 |
| Akero Therapeutics | Series B | $70M | Dec 2018 |
| Aprea Therapeutics | Series C | $50M | Nov 2018 |
| Innovent Biologics, Inc. | Series E | $150M | Apr 2018 |
Top Co-Investors
Janus Henderson Investors3 shared
Samsara BioCapital3 shared
Redmile Group2 shared
Cormorant Asset Management2 shared
Atlas Venture2 shared
Versant Ventures2 shared
RA Capital Management2 shared
RTW Investments2 shared
Sectoral Asset Management2 shared
HealthCap2 shared
OrbiMed2 shared
Novo Holdings2 shared
Access Biotechnology2 shared
Apple Tree Partners1 shared
venBio1 shared
Andera Partners1 shared
SR One1 shared
Adams Street1 shared
EDBI1 shared
Ally Bridge Group1 shared
Last updated: 3 March 2026